Spotlight On... Huya pads its pipeline with immuno-oncology deal; AstraZeneca's former R&D hub finds new life; and more...

Chinese-American biotech Huya Biosciences in-licensed a handful of early-stage treatments with potential in immuno-oncology, padding its pipeline behind a lead cancer therapy. The company is paying an undisclosed sum to China's Fudan University for the rest-of-world rights to some therapies that target the IDO pathway to help the immune system better attack malignancies. Huya said the deal is designed to augment its work on HBI-8000, an oral treatment that targets enzymes called HDACs, which play a role in regulating the growth of tumor cells. The drug is approved in China, and Huya has partnered with Eisai to develop it throughout Asia in a deal worth up to $270 million. More

@FierceBiotech: Tiny Celator surges on promising cancer data and preps an FDA submission. Article | Follow @FierceBiotech

@JohnCFierce: Gee, Lilly drops function as a co-primary endpoint for sola. Anyone a wee bit nervous? Release | Follow @JohnCFierce

> Three years after AstraZeneca ($AZN) closed its R&D hub in Cheshire, U.K., the site has found new life as the home of a public-private partnership between academia and small biotech companies. News

> The boom in microbiomics has spread to the field of immuno-oncology, as recent studies show gut bacteria could play a role in how the body responds to tumors. Story

Medical Device News

@FierceMedDev: Anne Wojcicki, Elizabeth Holmes, Andrew Conrad make 2016's most influential people in biopharma list. FierceBiotech feature | Follow @FierceMedDev

@VarunSaxena2: FDA panel set to review its first bioresorbable stent, Abbott's Absorb. Report | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Hospitals join drug price-fighting battalion with plans to crack down on spending. Report | Follow @EmilyWFierce

> NIH-funded researcher making progress on nature-inspired 'smart' contact lens. Story

> GE Healthcare JV rolls out digital pathology software for cancer diagnosis. More

> Philips readies for mid- to high-single-digit HealthTech growth with reorg, lighting disposal. Article

Pharma News

@FiercePharma: ICYMI yesterday: Patent challenger Bass wins another review bid, this time on Acorda's Ampyra. Story | Follow @FiercePharma

@CarlyHFierce: Ex-Sanofi, Schering CEOs were on a short list to replace Valeant chief Pearson: WSJ. More | Follow @CarlyHFierce

> Zydelig 'dead in the water' after trial deaths force Gilead to stop frontline studies. Report

> Specialty-drug spending set for double-digit leaps over the next 3 years: Express Scripts. More

Drug Delivery News

> 'Smart' diabetes patch uses real beta cells to react to blood sugar and release insulin. Story

> Artificial liposomes bypass immune system to release cardio drugs. More

> Harvard team develops blood-brain-barrier-on-a-chip to study drug delivery. Report

> EyeGate adds drug-delivering hydrogel to its pipeline with acquisition of Jade Therapeutics. Story

> Eli Lilly reports promising early-stage results for its fast-acting insulin formulation. Article

Pharma Manufacturing News

> Lupin plant in Goa smacked by the FDA. Report

> China's FDA urged to get track and trace system in place. Item

> Iran drugmaker agrees to build plant in Azerbaijan. Report

> Pfizer, Abbott cough syrups banned by Indian regulator in fight over opiates. Article

> Amgen strikes deal with Patheon for 'flexible manufacturing capacity.' Story

Pharma Asia News

> India still reviewing prospects for mandated cuts in drug prices. Item

> GSK's Witty hears the rhythm in China's drumbeat for lower prices. More

> India lifts alert on Roche's Avastin use for eye injection. Story

> SK Bio's epilepsy drug gets U.S. FDA exemption from PhIII efficacy step. News

> India's Dr. Reddy's works with Turkey's TR-Pharm on biosimilars. Article

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.